

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,424-T1)**

In the Application of:)
)
Zablocki et al.)
)
Serial No.: Not Assigned)
)
Filing Date: Concurrently Herewith)
)
For: C-Pyrazole A2A Receptor Agonists)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Pursuant to 37 C.F.R. §1.98(d), copies of references numbered 1-19 are not provided herewith, since they were previously provided in the parent case, U.S. Patent Application Serial No. 10/018,758, filed on March 12, 2002 and by the IB to the USPTO as an Elected Office as noted in PTO Form 905, "Notification of Missing Requirements" in relation to application no. PCT/US00/17095, of which the present application is a U.S. national phase and in the parent case, U.S. Patent Application Serial No. 09/338,327, filed on June 22, 1999 now U.S. Patent No. 6,214,807 issued April 10, 2001.

These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

U. S. PATENTS

1. Miyashita et al., U.S. Patent No. 5,189,027, issued February 23, 1993
2. Cristalli, U.S. Patent No. 5,593,975, issued January 14, 1997
3. Miyasaka et al., U.S. Patent No. 4,956,345, issued September 11, 1990
4. Kogi et al., U.S. Patent No. 5,270,304, issued December 14, 1993
5. Yamaguchi et al., U.S. Patent No. 5,459,254, issued October 17, 1995
6. Yamada, U.S. Patent No. 5,705,491, issued January 6, 1998
7. Khan et al., U.S. Patent No. 5,770,716, issued June 23, 1998
8. Morozumi et al., U.S. Patent No. 5,939,543, issued August 17, 1999
9. Zablocki et al., U.S. Patent No. 6,214,807, issued April 10, 2001
10. Verani, U.S. Patent No. 6,026,317, issued February 15, 2000

FOREIGN PATENT DOCUMENTS

11. Canadian Patent No. 965,411, published April 1, 1975
12. Japanese Patent No. 5[1993]-9197, published January 19, 1993
13. European Patent No. 0 354,638, published February 14, 1990

OTHER DOCUMENTS

14. Marumoto, et al., "Synthesis and Coronary Vaso-dilating Activity of 2-Substituted Adenosines", *Chem.. Pharm. Bull.* 23(4): 759-774 (1975).
15. Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", *Chem.. Pharm. Bull.* 27(4) 900-1003 (1979).
16. Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", *Bioorganic & Medicinal Chemistry*, 3:1377-1382 (1995).
17. Mager, et al., "Molecular simulation applied to 2-(N'-alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A₂ Agonists", *Eur J. Med. Chem*, 30:15-25 (1995).
18. Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'-ethyluronamide: Selective A₂ Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", *J. Med. Chem*,


37:1720-1726 (1994).

19. Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A₂ Receptor Agonists with Potent Antihypertensive Effects", *J. Med. Chem.* 35:241-252 (1992).

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: March 30, 2004

By:


A. Blair Hughes
Reg. No. 32,901

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Atty. Docket No.

99,424-T1

Serial No.

Not Assigned

Applicant:

Jeff Zablocki et al.

Filing Date:

Concurrently
Herewith

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate
	5,189,027	2/23/93	Miyashita et al.			
	5,593,975	1/14/97	Cristalli			
	4,956,345	9/11/90	Miyasaka et al.			
	5,270,304	12/14/93	Kogi et al.			
	5,459,254	10/17/95	Yamaguchi et al.			
	5,705,491	1/6/98	Yamada			
	5,770,716	6/23/98	Khan et al.			
	5,939,543	8/17/99	Morozumi et al.			
	6,214,807	4/10/01	Zablocki et al.			
	6,026,317	2/15/00	Verani			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	965,411	4/1/75	Canada				
	Hei 5[1993]-9197	1/19/93	Japan				
	0 354 638	2/14/90	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

Marumoto, et al., "Synthesis and Coronary Vaso-dilating Activity of 2-Substituted Adenosines", *Chem. Pharm. Bull.* 23(4): 759-774 (1975).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 99,424-T11	Serial No. Not Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Jeff Zablocki et al.	
		Filing Date: Concurrently Herewith	Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclasses	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

			Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3'5'-Cyclic Phosphate Analogs", Chem. Pharm. Bull. 27(4) 990-1003 (1979).
			Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", <i>Bioorganic & Medicinal Chemistry</i> , 3:1377-1382 (1995).
			Mager, et al., "Molecular simulation applied to 2-(N'alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A ₂ Agonists", <i>Eur J. Med. Chem</i> , 30:15-25 (1995).
			Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'ethyluronamide: Selective A ₂ Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", <i>J. Med. Chem</i> , 37:1720-1726 (1994).
			Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A ₂ Receptor Agonists with Potent Antihypertensive Effects", <i>J. Med. Chem.</i> 35:241-252 (1992).
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.